Health Care & Life Sciences » Biotechnology | Bioinvent International AB

Bioinvent International AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
81,713.00
46,932.00
15,925.00
71,284.00
45,014.00
38,548
SG&A Expense
94,104.00
103,231.00
110,499.00
134,196.00
146,106.00
163,076
EBIT
15,288.00
58,340.00
96,224.00
63,237.00
103,972.00
129,589
Unusual Expense
4,400.00
-
459.00
500.00
1,745.00
-
Non Operating Income/Expense
965.00
3,766.00
674.00
116.00
1,569.00
6,329
Pretax Income
18,039.00
53,985.00
95,028.00
62,587.00
100,528.00
123,163
Income Tax
-
-
4,347.00
-
-
-
Consolidated Net Income
18,039.00
53,985.00
90,681.00
62,587.00
100,528.00
123,163
Net Income
18,039.00
53,985.00
90,681.00
62,587.00
100,528.00
123,163
Net Income After Extraordinaries
18,039.00
53,985.00
90,681.00
62,587.00
100,528.00
123,163
Net Income Available to Common
18,039.00
53,985.00
90,681.00
62,587.00
100,528.00
123,163
EPS (Basic)
0.18
0.44
0.59
0.25
0.33
0.36
Basic Shares Outstanding
99,152.10
121,934.90
153,846.00
247,962.00
304,695.00
340,389.20
EPS (Diluted)
0.18
0.44
0.59
0.25
0.33
0.36
Diluted Shares Outstanding
99,152.10
121,934.90
153,846.00
247,962.00
304,695.00
340,389.20
EBITDA
12,392.00
56,299.00
94,574.00
62,241.00
101,092.00
124,528
Other Operating Expense
1.00
-
-
671.00
-
-
Non-Operating Interest Income
684.00
589.00
63.00
34.00
130.00
103

About Bioinvent International AB

View Profile
Address
Sölvegatan 41
Lund SN 223 70
Sweden
Employees -
Website http://www.bioinvent.com
Updated 07/08/2019
BioInvent International AB engages in the research and development of immuno-regulatory antibodies to treat cancer. Its clinical programs include BI-1206 for non-Hodgkin's lymphoma and chronic lymphatic leukaemia; TB-403 for paediatric brain tumors; and THR-317 for diabetic macular edema. Its technology platforms consist of F.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.